- Home
- PLCE vs MNOV Comparison
PLCE vs MNOV Comparison
Compare PLCE & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLCE
- MNOV
- Stock Information
- Founded
- PLCE 1969
- MNOV 2000
- Country
- PLCE United States
- MNOV United States
- Employees
- PLCE N/A
- MNOV N/A
- Industry
- PLCE Clothing/Shoe/Accessory Stores
- MNOV Biotechnology: Pharmaceutical Preparations
- Sector
- PLCE Consumer Discretionary
- MNOV Health Care
- Exchange
- PLCE Nasdaq
- MNOV Nasdaq
- Market Cap
- PLCE 76.8M
- MNOV 76.0M
- IPO Year
- PLCE 1997
- MNOV 2005
- Fundamental
- Price
- PLCE $5.71
- MNOV $1.45
- Analyst Decision
- PLCE Hold
- MNOV Strong Buy
- Analyst Count
- PLCE 3
- MNOV 1
- Target Price
- PLCE $8.33
- MNOV $9.00
- AVG Volume (30 Days)
- PLCE 519.2K
- MNOV 16.4K
- Earning Date
- PLCE 04-11-2025
- MNOV 05-08-2025
- Dividend Yield
- PLCE N/A
- MNOV N/A
- EPS Growth
- PLCE N/A
- MNOV N/A
- EPS
- PLCE N/A
- MNOV N/A
- Revenue
- PLCE $1,386,269,000.00
- MNOV N/A
- Revenue This Year
- PLCE N/A
- MNOV N/A
- Revenue Next Year
- PLCE N/A
- MNOV N/A
- P/E Ratio
- PLCE N/A
- MNOV N/A
- Revenue Growth
- PLCE N/A
- MNOV N/A
- 52 Week Low
- PLCE $4.77
- MNOV $1.12
- 52 Week High
- PLCE $19.74
- MNOV $2.55
- Technical
- Relative Strength Index (RSI)
- PLCE 35.07
- MNOV 50.85
- Support Level
- PLCE $5.32
- MNOV $1.36
- Resistance Level
- PLCE $6.09
- MNOV $1.35
- Average True Range (ATR)
- PLCE 0.92
- MNOV 0.09
- MACD
- PLCE -0.20
- MNOV 0.03
- Stochastic Oscillator
- PLCE 9.22
- MNOV 91.43
About PLCE Children's Place Inc. (The)
Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It design, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.